{"id":"W2007734777","doi":"10.1089/cbr.2000.15.15","title":"Pretargeted Radioimmunotherapy (PRIT™) for Treatment of Non-Hodgkin's Lymphoma (NHL): Initial Phase I/II Study Results","year":2000,"lang":"en","type":"article","venue":"Cancer Biotherapy and Radiopharmaceuticals","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Radioimmunotherapy; Pretargeting; Medicine; Biodistribution; Conjugate; Nuclear medicine; Rituximab; Lymphoma; Pharmacokinetics; Antibody; Internal medicine; Chemistry; Monoclonal antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002682493,0.0003441723,0.0008317921,0.0001347917,0.0002725142,0.00002934025,0.0001156165,0.0001385812,0.001229003],"category_scores_gemma":[0.000008855335,0.0002423442,0.0002444376,0.0002351906,0.0003534548,0.0001083376,0.00001067796,0.00007424925,0.000003620684],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001169421,"about_ca_system_score_gemma":0.0002160898,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002230102,"about_ca_topic_score_gemma":0.00000487805,"domain_scores_codex":[0.9979643,0.0001042541,0.0006022078,0.0005133144,0.0003168395,0.0004991277],"domain_scores_gemma":[0.9989678,0.0002046455,0.0000920373,0.0003049988,0.0001109279,0.000319545],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.07664491,0.006421204,0.0007193519,0.0001328303,0.00141885,0.00006746934,0.003154371,0.00000569163,0.1032993,0.00002185086,0.0004513888,0.8076628],"study_design_scores_gemma":[0.1280711,0.04235062,0.004727974,0.0001439787,0.0003702538,0.0000982351,0.0001466557,0.002895204,0.1820384,0.00002933372,0.6386678,0.0004604973],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.965618,0.02805833,0.00004146552,0.002186312,0.0001767061,0.002785991,0.0006243191,0.00003909631,0.0004697627],"genre_scores_gemma":[0.9149006,0.07638565,0.0005454127,0.0008915407,0.0007625818,0.0004045331,0.00006042927,0.00005554484,0.005993711],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8072023,"threshold_uncertainty_score":0.999684,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07038171382198578,"score_gpt":0.4769027952507788,"score_spread":0.406521081428793,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}